(1)

Regulation (EU) 2015/2283 provides that only novel foods authorised and included in the Union list may be placed on the market within the Union.

(2)

Pursuant to Article 8 of Regulation (EU) 2015/2283, Commission Implementing Regulation (EU) 2017/2470 (2) establishing a Union list of authorised novel foods was adopted.

(3)

Commission Implementing Decision (EU) 2016/1190 (3) authorised the placing on the Union market of trans-resveratrol as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (4), to be used in food supplements as defined in Directive 2002/46/EC of the European Parliament and of the Council (5), in capsule or tablet form, for the adult population.

(4)

On 31 January 2020, the company DSM Nutritional Products Europe (‘the applicant’) submitted an application to the Commission in accordance with Article 10(1) of Regulation (EU) 2015/2283 to change the conditions of use of the novel food ‘trans-resveratrol’. The applicant requested the modification of the delivery formats for food supplements containing the novel food trans-resveratrol, in particular removing the specific delivery formats, capsule or tablet form, as the only allowed forms of the food supplements as listed in the Union list.

(5)

The applicant considers that the modification of the delivery formats for food supplements containing trans-resveratrol is necessary, as it would allow trans-resveratrol to be used in other food supplement forms than capsules or tablets.

(6)

There are a number of novel foods currently authorised in food supplements and listed in the Union list of novel foods for which the delivery formats have not been specified. Therefore, the modification of the delivery formats for food supplements containing trans-resveratrol would ensure consistency regarding the conditions of use of food supplements, as well as provide more options to food business operators to follow consumer preferences.

(7)

The Commission did not request an opinion from the European Food Safety Authority in accordance with Article 10(3) as the change of the conditions of use of the novel food trans-resveratrol by removing the specific delivery formats of food supplements is not liable to have an effect on human health. Therefore, it is appropriate to change the conditions of use of the novel food trans-resveratrol to authorise its use in any form of food supplements at the previously authorised maximum level.

(8)

The maximum level of trans-resveratrol in food supplements authorised by Implementing Decision (EU) 2016/1190 and indicated in the Union list of novel foods remains the same. The safety considerations that supported the authorisation of trans-resveratrol in food supplements remain valid and the removal of the specific delivery formats of food supplements does not pose safety concern.

(9)

The Annex to Implementing Regulation (EU) 2017/2470 should therefore be amended accordingly.

(10)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,